Velinotamig

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameVelinotamig
Drug Alias NameGR-1803
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-BCMAAnti-CD3
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCullinan Therapeutics IncChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A